Clariant and private investment firm CD&R are in talks to acquire Ashland in an all-cash deal valuing the company at $3.39B, Bloomberg News reported on Sunday. The potential transaction follows pressure from activist investors who argued the target was undervalued. The deal would reshape the specialty chemicals sector in the United States.

Inside the Acquisition Talks